Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30922674 | 0.91 | CYP4F2 (0.34) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30922716 | 0.86 | CYP4F2 (0.34) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30922605 | 0.84 | CYP4F2 (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL23043733 | 0.84 | CYP4F2 (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30922796 | 0.84 | RXRA (0.41) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL25795327 | 0.83 | RXRA (0.40) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL21243880 | 0.82 | CYP4F2 (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30922886 | 0.82 | RXRA (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29680540 | 0.82 | CYP4F2 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL24536354 | 0.82 | CYP4F2 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |